Amedisys Management

Management Kriterienprüfungen 1/4

Amedisys CEO ist Richard Ashworth , ernannt in Apr 2023, hat eine Amtszeit von 1.58 Jahren. Die jährliche Gesamtvergütung beträgt $16.97M , bestehend aus 4.1% Gehalt und 95.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.088% der Aktien des Unternehmens, im Wert von $2.59M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.6 Jahre bzw. 5 Jahre.

Wichtige Informationen

Richard Ashworth

Geschäftsführender

US$17.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts4.1%
Amtszeit als Geschäftsführer1.6yrs
Eigentum des Geschäftsführers0.09%
Durchschnittliche Amtszeit des Managements1.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5yrs

Jüngste Management Updates

Recent updates

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Nov 05

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Apr 10
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Feb 25
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Feb 10
Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jan 03
At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Dec 16
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Nov 12
Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Sep 19
Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04
An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04
Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04
At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05
Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06
Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20
Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19
Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18
These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18
Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28
Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02
It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Richard Ashworth im Vergleich zu den Einnahmen von Amedisys verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$83m

Jun 30 2024n/an/a

US$92m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$17mUS$692k

-US$10m

Vergütung im Vergleich zum Markt: RichardDie Gesamtvergütung ($USD16.97M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD6.60M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Richard mit der Unternehmensleistung zu vergleichen.


Geschäftsführer

Richard Ashworth (49 yo)

1.6yrs

Amtszeit

US$16,974,025

Vergütung

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Richard Ashworth
President1.6yrsUS$16.97m0.088%
$ 2.6m
Scott Ginn
Executive VP7.1yrsUS$4.45m0.077%
$ 2.3m
Denise Bohnert
Chief Compliance Officer5.2yrsUS$1.28mkeine Daten
Nick Muscato
Chief Strategy Officerno dataUS$1.37m0.0065%
$ 191.6k
Allyson Guidroz
Chief Accounting Officer & Principal Accounting Officer1.3yrskeine Daten0.0097%
$ 285.0k
Pete Hartley
CTO & Senior VP of Business Operations Systemsno datakeine Datenkeine Daten
Keith Blanchard
Acting Chief Information Officerless than a yearkeine Datenkeine Daten
Jennifer Griffin
Senior VP2.1yrskeine Daten0.054%
$ 1.6m
Kendra Kimmons
VP of Marketing & Communications & Media Relationsno datakeine Datenkeine Daten
Caitlin Franklin
Acting Chief People Officerless than a yearkeine Datenkeine Daten
Francis Mayer
Senior Vice President of Developmentno datakeine Datenkeine Daten

1.6yrs

Durchschnittliche Betriebszugehörigkeit

47.5yo

Durchschnittliches Alter

Erfahrenes Management: AMEDDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.6 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Richard Ashworth
President1.6yrsUS$16.97m0.088%
$ 2.6m
Paul Kusserow
Chairman9.9yrsUS$4.00m1.33%
$ 39.3m
Bruce Perkins
Independent Director9.6yrsUS$267.62k0.063%
$ 1.9m
Vickie Capps
Independent Director5yrsUS$277.62k0.020%
$ 580.4k
Molly Coye
Independent Director5yrsUS$267.62k0.017%
$ 490.5k
Julie Klapstein
Lead Independent DIrector8.6yrsUS$282.62k0.039%
$ 1.1m
Jeffrey Rideout
Independent Director8.6yrsUS$267.62k0.018%
$ 537.1k
Teresa Kline
Independent Director5yrsUS$272.62k0.020%
$ 580.4k
Ivanetta Samuels
Independent Director3.9yrsUS$252.62k0.013%
$ 380.8k

5.0yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: AMEDDie Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).